Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142 on ClinicalTrials.gov · last registry update 2022-01-14

Finished July 2019, after enrolling 70 people. Primary outcome, as filed: Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score. exenatide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Massachusetts, Worcester
Sponsor type: Other
Enrollment: 70
Started: 2014-09
Primary completion: 2019-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score

Conditions studied

Schizophrenia · Schizoaffective Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.